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S U M M A R Y
Background: The tuberculin skin test (TST) is commonly used for the diagnosis of latent tuberculosis
infection (LTBI) in non-bacille Calmette–Gue´rin (BCG) vaccination settings. In recent years, attention has
been drawn to interferon-gamma release assays (IGRAs), especially in BCG-vaccinated populations. In
this study, we evaluated the TST and a new whole blood IGRA in BCG-vaccinated individuals during a
tuberculosis (TB) outbreak in China.
Methods: A TB outbreak occurred at a university in Dalian, China from March to November 2010. The TST
and a whole blood IGRA were used to screen for TB infection. The correlation between exposure levels,
TST, and the IGRA were evaluated.
Results: We found that agreement between the IGRA and TST was poor (kappa 0.182–0.290). IGRA
positivity was associated with the level of exposure, and IGRA positivity and the level of exposure were
risk factors for TB incidence. Neither the IGRA nor the TST alone picked up all TB incidences. However, if a
10 mm cutoff for the TST was used in the highest risk exposure group and IGRA positivity was used in the
other risk groups, 19 of the 20 (95%) TB cases were identiﬁed.
Conclusions: A recommended preventive treatment regimen for China should be based on the level of
exposure in conjunction with IGRA and TST test results.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
China is one of the world’s 22 high burden countries for
tuberculosis (TB) infection. As a consequence, TB outbreaks in
settings such as those in which individuals remain in close contact
for long periods of time are a serious public health problem. The
screening methods commonly used during TB outbreaks in China
are chest X-rays and the tuberculin skin test (TST). However,
individuals who have received the mandatory bacille Calmette–
Gue´rin (BCG) vaccine in China may have a cross-reaction to TST. In
recent years, whole blood interferon-gamma release assays
(IGRAs) have become a recommended method for the detection
of latent TB infections (LTBI) in the USA and Japan.1 In spite of this,* Corresponding author. Tel.: +86 411 3954 7906; fax: +86 411 3954 7902.
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http://dx.doi.org/10.1016/j.ijid.2012.03.003IGRAs have not been fully evaluated in either BCG-vaccinated
populations in high TB burden countries or in outbreak settings.
The TST, which is based on a delayed-type hypersensitivity
response to puriﬁed protein derivative (PPD) from Mycobacterium
tuberculosis, is still the primary method used in the diagnosis of
LTBI in China. The sensitivity and speciﬁcity of the TST are
dependent upon the cutoff value used to deﬁne a positive result in
a given population. The speciﬁcity is increased (and sensitivity
decreased) by progressively increasing the reaction size that is
classiﬁed as a positive test result. The speciﬁcity of the skin test is
variable and dependent primarily upon the likelihood of cross-
reactions with non-tuberculous mycobacteria.2 In addition,
distinguishing between TST reactions caused by natural mycobac-
terial infections and those caused by BCG is challenging and can
lead to the generation of false-positive results.2,3 It has also been
shown that repeated TST testing or two-step testing can boost
BCG-induced sensitivity.4,5 The TST also requires a second visit in
which an experienced healthcare worker must read the diameter
of the induration.ses. Published by Elsevier Ltd. All rights reserved.
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from the RD1-region of M. tuberculosis, which is not present in BCG
or in most non-tuberculous mycobacteria.6,7 This reduces the
chances of cross-reactivity and makes IGRAs more suitable for use
in BCG-vaccinated populations. Studies have shown that IGRAs
may be valuable for the diagnosis of recent infections.8,9 Because
active TB occurs mainly in the ﬁrst year after exposure, IGRAs could
be used to detect contact infections thereby limiting TB outbreaks.
Another advantage of whole blood IGRAs is that they require only a
simple blood draw at a single visit.
The aim of our study was to compare the TST and a new IGRA
(ASACIR.TB; A.TB) during an outbreak in China. We examined the
correlation between exposure levels, TST and IGRA results, and the
observed incidence of TB during the outbreak. The outbreak
occurred between March and November 2010 in Dalian, China. The
520 volunteer subjects were divided into six groups based upon
their risk of exposure. Three methods were used for patient
screening and LTBI detection: TST, A.TB, and chest X-ray. Since
IGRAs have not been recommended as a TB diagnostic tool by the
China Centers for Disease Control and Prevention (China CDC), the
anti-TB treatment was administered to infected subjects as deﬁned
by a TST induration of 15 mm. This study was approved by the
Ethics Committee of Dalian Tuberculosis Hospital and informed
consent was obtained from all participants.
2. Materials and methods
2.1. Case review
The TB outbreak occurred among students enrolled at a
university in Dalian in September 2007. The group included 520
students (361 male and 159 female) with an average age of 21.5
years. Male and female students lived in separate buildings.
Among the members of this group, 98.7% had received a BCG
vaccination.
The index TB case was a 21-year-old male diagnosed with active
pulmonary TB (PTB) on March 6, 2010. The patient had coughing
symptoms for 4 weeks before diagnosis. Between March and
November of 2010, a total of 19 secondary cases of active TB were
diagnosed.
2.2. Patient diagnosis
The index case appeared smear-positive. Of the 19 secondary
cases, 10 were diagnosed as PTB cases: three appeared smear-
negative but culture-positive, two were conﬁrmed with TB by
biopsy using a bronchoscope, and ﬁve (with the typical TB imaging
characteristics but small lesions) were diagnosed with active TB
after effective anti-TB treatment. In the nine remaining secondary
cases of simple TB pleurisy, the lymphocyte and adenosineFigure 1. Floor plan showing rooms of level 1 and level 2 exposure; R, room. Students liv
grouped into level 2 exposure. Asterisks denote a TB case; the index case occurred in deaminase (ADA) levels were elevated in the pleural effusion.
During anti-TB treatment all pleurisy cases experienced absorption
of the pleural effusion.
2.3. Contact classiﬁcation
The 520 volunteer subjects were divided into six groups
based on their risk of exposure (Figure 1). Level 1 (L1) students
lived in the same or consecutive rooms (R1–R11) and frequently
studied in the same classroom as the index case. Level 2 (L2)
students lived on the same ﬂoor (R12–R33) and frequently
studied in the same classroom as the index case. Level 3 (L3)
students lived on different ﬂoors in the same building and
frequently studied in the same classroom as the index case. Level
4 (L4) students did not live in the same building but frequently
studied in the same classroom as the index case (mainly
females). Level 5 (L5) students lived on a different ﬂoor in the
same building as the index case but studied in different
classrooms (mainly males). Level 6 (L6) students did not live
in the same building and studied in different classrooms (mainly
females) to the index case. Based on the above criteria, there
were 39 subjects in level 1, 82 in level 2, 116 in level 3, 93 in level
4, 126 in level 5, and 64 in level 6.
2.4. Screening methods
For TST screening 0.1 ml (5 IU) of PPD was injected under the
palmar skin of the left upper forearm and the diameter of
induration (DI) measured 72 h post injection. The ﬁrst round of TST
testing was carried out on 505 of the 520 subjects (97.1%) in
September 2007. The second round of TST testing was carried out
on 520 subjects (100%) in May 2010.
The A.TB IGRA was developed by Haikou VTI Biological Institute,
Hainan, China. This assay uses Haikou VTI’s patented technology (US
patent number 7754219), which enables the intracellular delivery of
full length culture ﬁltrate protein 10 (CFP-10) and early secretory
antigenic target 6 (ESAT-6) antigens to stimulate antigen-speciﬁc T
cells through the classic major histocompatibility complex class 1
(MHC-1) pathway.10,11 The assay was performed according to the
user manual. In brief, negative control phosphate buffered saline
(PBS) (N), positive control ConA (P), and the TB stimulators CFP-10
and ESAT-6 (T) were each mixed with 1 ml of fresh heparinized
whole blood and incubated for approximately 24 h at 37 8C. The
plasma was then collected and stored at 4 8C for up to 2 weeks or at
20 8C for long-term storage. The interferon-gamma levels in the
plasma were then determined by ELISA. If N was <0.5 IU/ml and (T 
N)/(P  N)  0.6, or if N was >0.5 IU/ml and (T  N)/(P  N)  0.85 the
test was determined to be positive, otherwise the result was
negative. Blood testing was performed following the second TST
screening. All 520 subjects received the test.ing in R1–R11 were grouped into level 1 exposure; students living in R12–R33 were
R3. Note: The window on the left was always closed.
Figure 2. Trends in IGRA positivity and TST results before and after the outbreak (IGRA, interferon-gamma release assay; TST, tuberculin skin test; DI, diameter of induration).
There was a signiﬁcant difference between the DI values before and after the outbreak. The TST curve shifted signiﬁcantly to the right, with the intersection of the two curves
(before and after the outbreak) at the 10–11-mm interval. The trend of the TST curve was consistent with the IGRA positivity curve.
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Anti-TB treatment was administered based on a TST of
15 mm. Beginning in April 2010, 41 students voluntarily
accepted anti-TB preventive treatment. In all cases a 6-month
oral course of isoniazid was administered.
2.6. Statistical methods
Data were analyzed using SPSS 15.0. Kappa was used to
evaluate concordance between the different methods. A p-value of
<0.05 was considered statistically signiﬁcant. In order to
determine risk factors for TB incidence, SPSS 15.0 software
was utilized to carry out the binary logistic regression analysis
using secondary TB cases as the dependant variable and TST
15 mm, TST 10 mm, A.TB result, and the level of exposure as
covariates.
3. Results
3.1. IGRA positivity was signiﬁcantly associated with the level of
exposure
In 2007, 505 of the 520 subjects in this study were examined by
TST and the average DI was 7.1  4.5 mm. During the outbreak in
2010, 520 subjects were retested by TST and the average DI was
13  5 mm. There was a signiﬁcant difference between the DI values
before and after the outbreak (p = 0.00). After the outbreak, the TSTTable 1
The discordance between the ASACIR.TB IGRA and the TST
Risk of exposure level
L1 (n = 39) L2 (n = 82) L3 (n = 116
A.TB-positive
TST 10 mm 28 43 51 
TST <10 mm 0 8 4 
TST 15 mm 20 29 35 
TST <15 mm 8 22 20 
A.TB-negative
TST 10 mm 11 25 44 
TST <10 mm 0 6 17 
TST 15 mm 8 16 23 
TST <15 mm 3 15 38 
Concordance rate
A.TB vs. PPD (10 mm) 71.8% 59.8% 58.6% 
A.TB vs. PPD (15 mm) 59.0% 53.7% 62.9% 
10 mm was used as the TST cutoff. A.TB, ASACIR.TB IGRA; TST, tuberculin skin test; PPcurve shifted signiﬁcantly to the right (see Figure 2), with the
intersection of the two curves (before and after the outbreak) at the
10–11-mm interval.
Although the trend of the TST curve was consistent with that of
the IGRA positivity curve, the agreement between the IGRA and
TST was poor (Table 1). The overall kappa value between the IGRA
and TST 10 mm was 0.182, and between the IGRA and TST
15 mm was 0.290. The overall TST positivity was 79.0% using
10 mm as the cutoff and 47.3% using 15 mm as the cutoff, while the
IGRA positivity was 41.7%. The overall rate of concordance between
the IGRA and TST was 64.8% at the 15 mm cutoff and 55.0% at the
10 mm cutoff.
The volunteers were classiﬁed into six groups based on the risk
of exposure to the index case. Level 1 was at the highest risk of
exposure. IGRA positivity was 71.8%, 62.2%, 47.4%, 40.9%, 23.8%,
and 20.3% in groups L1 to L6, respectively (Table 2); IGRA positivity
was signiﬁcantly associated with the level of exposure (p < 0.05).
However, using the 10 mm cutoff point, the positivity of the TST
was 100%, 82.9%, 81.9%, 89.2%, 72.2%, and 56.3% in groups L1 to L6,
respectively; and using the 15 mm cutoff, the positivity of the TST
was 71.8%, 54.9%, 50%, 48.4%, 42.1%, and 26.6% in groups L1 to L6,
respectively (Table 2).
3.2. Level of exposure and IGRA positivity are risk factors for TB
incidence
In order to establish the risk factors for incidence, the
volunteers who accepted preventive treatment (n = 41) and the) L4 (n = 93) L5 (n = 126) L6 (n = 64) Sum
36 28 10 196
2 2 3 19
28 21 6 139
10 9 7 76
47 62 26 215
8 34 25 90
17 32 11 107
38 64 40 198
47.3% 49.2% 54.7% 55.0%
71.0% 67.5% 71.9% 64.8%
D, puriﬁed protein derivative; IGRA, interferon-gamma release assay.
Table 2
Comparison between the ASACIR.TB IGRA and the TST in the different risk of exposure level groups
L1 (n = 39) L2 (n = 82) L3 (n = 116)
Cases TB (n = 9) Cases TB (n = 3) Cases TB (n = 5)
A.TB Pos 28 (71.8%) 6 51 (62.2%) 3 55 (47.4%) 4
Neg 11 (28.2%) 3 31 (37.8%) 0 61 (52.6%) 1
TST 10 mm Pos 39 (100%) 9 68 (82.9%) 2 95 (81.9%) 3
Neg 0 0 14 (17.1%) 1 21 (18.1%) 2
TST 15 mm Pos 28 (71.8%) 5 45 (54.9%) 1 58 (50%) 2
Neg 11 (28.2%) 4 37 (45.1%) 2 58 (50%) 3
L4 (n = 93) L5 (n = 126) L6 (n = 64)
Cases TB (n = 3) Cases TB (n = 0) Cases TB (n = 0)
A.TB Pos 38 (40.9%) 3 30 (23.8%) 0 13 (20.3%) 0
Neg 55 (59.1%) 0 96 (76.2%) 0 51 (79.7%) 0
TST 10 mm Pos 83 (89.2%) 3 91 (72.2%) 0 36 (56.3%) 0
Neg 10 (10.8%) 0 35 (27.8%) 0 28 (43.8%) 0
TST 15 mm Pos 45 (48.4%) 3 53 (42.1%) 0 17 (26.6%) 0
Neg 48 (51.6%) 0 73 (57.9%) 0 47 (73.4%) 0
10 mm was used as the TST cutoff. A.TB, ASACIR.TB IGRA; TST, tuberculin skin test; IGRA, interferon-gamma release assay.
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regression analysis (n = 478/519) was conducted with all 19
secondary cases as dependant variables; TST 15 mm, TST
10 mm, A.TB result, and level of exposure were the covariates.
We found that the level of exposure (p = 0.00, odds ratio 2.642) and
IGRA positivity (p = 0.04, odds ratio 3.359) were the risk factors for
subsequent TB incidence.
3.3. Anti-TB preventive treatment and subsequent TB incidence
IGRAs are not included in the Guidelines for tuberculosis control
in the schools of China, so the preventive therapy started at the end
of April was based on a TST value 15 mm. Treatment consisted of
the administration of oral isoniazid for a 6-month period. During
the 12-month follow-up period there were no secondary cases in
the 41 individuals in the high exposure groups (levels 1–4) whoFigure 3. Relationship between TB incidence, ASACIR.TB IGRA, TST, and the level of exp
assay; TST, tuberculin skin test). The stars designate each TB case. Of a total of 20 TB cases,
able to identify all cases. Among the 520 students, 215 (41.3%) appeared IGRA-positiveagreed to preventive therapy. Of the 478 individuals not taking
preventative medication there were 13 subsequent TB cases during
the peak incidence period (March to June). Eight of these cases had
a TST of <15 mm. In the groups with relatively low exposure (L5
and L6), there were a number of TST 15 mm and IGRA-positive
subjects, but no secondary cases were found during the 12-month
follow-up period.
Of a total of 20 TB cases, 16 were detected by IGRA, 17 by TST
using a 10 mm cutoff and 11 using a 15 mm cutoff. No assay by
itself was able to identify all cases (see Figure 3).
4. Discussion
As a rule, a negative TST indicates that a person has not been
affected by TB. In this study, two secondary TB cases had TST values
of 0 mm and 3 mm but appeared IGRA-positive. These couldosure (L, level of exposure; A.TB, ASACIR.TB IGRA; IGRA, interferon-gamma release
 16 were detected by IGRA and 11 by TST using a 15 mm cutoff. No assay by itself was
 and 246 (47.3%) appeared TST-positive using a 15 mm cutoff.
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5–25% of patients with active TB show a negative skin test
(10 mm cutoff).12,13 However, since the index case was reported
on March 6 and these two cases were identiﬁed on April 14 and 21,
the negative TST could have been due to a delayed response.
Generally, from 2 to 12 weeks is required after primary infection
for the skin test conversion to occur.14
In this study, 70.5% of those tested were IGRA-negative/TST-
positive when using a TST cutoff of >10 mm, and 34.0% were IGRA-
negative/TST-positive when using a TST cutoff of >15 mm. This
suggests either a lack of sensitivity for the IGRA, as reported in
previous studies,15,16 or perhaps a lower sensitivity for older LTBI
and a better sensitivity for recent infections. However, 8.8% of those
tested were IGRA-positive/TST-negative when using a TST cutoff of
<10 mm, and 35.3% when using a TST cutoff of <15 mm. This may
contradict the assumption of a lower sensitivity for IGRAs. In
addition, we found that IGRA positivity was signiﬁcantly associated
with the level of exposure, which may imply that it was more likely
to suggest a recent infection, as reported elsewhere.17–20
A total of four TB cases appeared IGRA-negative/TST-positive,
with indurations of 10–13 mm, which indicates an IGRA false-
negative. An alternative interpretation is that the response to the
A.TB stimulators was diminished by a high bacterial load.21
Interestingly, three of the four cases had pleural effusion. As
estimated by meta-analysis, 25% of TB pleurisy would be missed by
IGRAs.22 In our study, seven out of nine (77.8%) TB pleurisy cases
were identiﬁed by IGRA. Certainly, this observation should be
further conﬁrmed by future studies in larger numbers of patients
and in longitudinal studies with clinical outcomes. Therefore, in
the high level contact group in a TB outbreak, a negative IGRA
result may not exclude the possibility of the subsequent
development of active TB.
The study revealed that the level of exposure and IGRA
positivity were risk factors for the incidence of TB. Preventive
treatment was administered based on a TST 15 mm, and after 6
months of treatment, no cases were reported from this group.
However, of a total of 20 TB cases, nine (45%) had a TST of <15 mm,
which suggests that the regimen currently used in China for the
detection of TB during an outbreak is not sufﬁcient.
Neither the IGRA nor the TST alone picked up all incidences of
TB. However, if a TST of 10 mm was used as an indicator for the
level 1 exposure group and IGRA positivity was used as an indicator
for levels 2–4, this would pick up 95% (19/20) of the TB cases. The
one missed case (TB pleurisy) had a TST of 20 mm and was from the
level 4 exposure group, a group that had few infections (Figure 3).
As mentioned previously, the case of TB pleuritis might be missed
by IGRAs.
A limitation of this study is that a detailed evaluation of the
occurrence of LTBI during the 2-year period from 2007 to 2010
(from student enrolment into the university to TB outbreak) has
not been carried out, which could affect the conclusions drawn in
this paper. Furthermore, the follow-up period was not long
enough, which might have an impact on the conclusions.
In conclusion, the level of exposure and IGRA positivity were
found to be risk factors for TB incidence during an outbreak in a
high TB burden country. A preventive treatment regimen is
recommended based on the level of exposure, in conjunction with
the results of IGRA and TST tests.
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